Difference between revisions of "Increasing Willingness and/or Ability of Governments to Sponsor Biotech Research."
Line 24: | Line 24: | ||
==Timing:== | ==Timing:== | ||
• 2000 – 2005 Biotech strategies by several countries | • 2000 – 2005 Biotech strategies by several countries<br> | ||
• 2001: Healthcare Spending by US Goverment passes 20% of governmental budget | • 2001: Healthcare Spending by US Goverment passes 20% of governmental budget<br> | ||
• 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe | • 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe<br> | ||
• 11/2002: First People suffering from SARS identified in Province of Guangdong, China | • 11/2002: First People suffering from SARS identified in Province of Guangdong, China<br> | ||
• 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution | • 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution<br> | ||
==Web Resources:== | ==Web Resources:== | ||
• http://www.who.int/countries/en/ | • http://www.who.int/countries/en/ |
Revision as of 13:12, 2 December 2005
Description:
Many governments are willing to support and sponsor fundamental research in biotech by massive funds, many have declared biotech a core issue in their economic strategy and many are trying to attract biotech companies to move production sites and research activities to the territory of their countries. A biotech company is almost always welcome.
Enablers:
• Biotech has been declared a core topic of the economic policy of many governments
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth
• Lack of private venture capital in certain countries triggering calls for government sponsorship
• Worldwide diseases
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine
• Few other alternatives for Research Sponsorship
Inhibitors:
• Budgetary limitations
• Exploding healthcare costs
• Priorities other than biotech
• Other promising opportunities for investment and sponsorship
Paradigms:
• Perception of biotechnology as a core topic for the competitiveness of a nation
Experts:
• Ernst & Young; 2005; Beyond Borders, Global Biotechnology Report 2005
Timing:
• 2000 – 2005 Biotech strategies by several countries
• 2001: Healthcare Spending by US Goverment passes 20% of governmental budget
• 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe
• 11/2002: First People suffering from SARS identified in Province of Guangdong, China
• 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution